- Home
- ARVN vs CYRX Comparison
ARVN vs CYRX Comparison
Compare ARVN & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- CYRX
- Stock Information
- Founded
- ARVN 2015
- CYRX 1999
- Country
- ARVN United States
- CYRX United States
- Employees
- ARVN N/A
- CYRX N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- CYRX Health Care
- Exchange
- ARVN Nasdaq
- CYRX Nasdaq
- Market Cap
- ARVN 456.2M
- CYRX 438.7M
- IPO Year
- ARVN 2018
- CYRX N/A
- Fundamental
- Price
- ARVN $7.90
- CYRX $8.50
- Analyst Decision
- ARVN Buy
- CYRX Strong Buy
- Analyst Count
- ARVN 22
- CYRX 10
- Target Price
- ARVN $20.21
- CYRX $11.70
- AVG Volume (30 Days)
- ARVN 1.8M
- CYRX 1.1M
- Earning Date
- ARVN 10-29-2025
- CYRX 08-05-2025
- Dividend Yield
- ARVN N/A
- CYRX N/A
- EPS Growth
- ARVN N/A
- CYRX N/A
- EPS
- ARVN N/A
- CYRX 1.35
- Revenue
- ARVN $372,800,000.00
- CYRX $237,879,000.00
- Revenue This Year
- ARVN $4.87
- CYRX N/A
- Revenue Next Year
- ARVN N/A
- CYRX $9.08
- P/E Ratio
- ARVN N/A
- CYRX $6.31
- Revenue Growth
- ARVN 299.57
- CYRX 24.93
- 52 Week Low
- ARVN $5.90
- CYRX $4.58
- 52 Week High
- ARVN $29.61
- CYRX $9.48
- Technical
- Relative Strength Index (RSI)
- ARVN 60.55
- CYRX 52.20
- Support Level
- ARVN $7.62
- CYRX $8.57
- Resistance Level
- ARVN $8.22
- CYRX $8.95
- Average True Range (ATR)
- ARVN 0.31
- CYRX 0.43
- MACD
- ARVN 0.10
- CYRX -0.05
- Stochastic Oscillator
- ARVN 76.98
- CYRX 20.00
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.